Author:
Koršić Marta,Muršić Davorka,Badovinac Sonja,Božina Nada,Roglić Mihovil,Jakopović Marko,Čučević Branka
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology
Reference19 articles.
1. Reck M, Popat S, Reinmuth N, De Ruysscher D, Kerr KM, Peters S (2014) Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 25(Suppl 3):iii27–iii39
2. Steins M, Thomas M, Geißler M (2014) Erlotinib. Recent Results Cancer Res 201:109–123
3. Gridelli C, Maione P, Bareschino MA, Schettino C, Sacco PC, Ambrosio R et al (2010) Erlotinib in the treatment of non-small cell lung cancer: current status and future developments. Anticancer Res 30(4):1301–1310
4. Tiseo M, Andreoli R, Gelsomino F, Mozzoni P, Azzoni C, Bartolotti M et al (2014) Correlation between erlotinib pharmacokinetics, cutaneous toxicity and clinical outcomes in patients with advanced non-small cell lung cancer (NSCLC). Lung Cancer 83(2):265–271
5. SEARCH Collaborative Group, Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F, Gut I, Lathrop M, Collins R (2008) SLCO1B1 variants and statin-induced myopathy-a genomewide study. N Engl J Med 359(8):789–799
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献